After Cowen & Co. and J.P. Morgan gave Ultragenyx Pharmaceutical (NASDAQ: RARE) a Buy rating last month, the company received another Buy, this time from Morgan Stanley. Analyst Jeffrey Hung maintained a Buy rating on Ultragenyx Pharmaceutical today and set a price target of $77.00. The company’s shares closed last Monday at $59.83.
According to TipRanks.com, Hung is a 5-star analyst with an average return of 27.7% and a 70.3% success rate. Hung covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics, Prevail Therapeutics, and Acceleron Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx Pharmaceutical with a $70.00 average price target, representing a 13.4% upside. In a report issued on January 9, Cowen & Co. also maintained a Buy rating on the stock with a $59.00 price target.
Based on Ultragenyx Pharmaceutical’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $113 million. In comparison, last year the company had a GAAP net loss of $87.83 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.